Protagenic Therapeutics, Inc.

Equities

PTIX

US74365N2027

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 12:34:09 29/05/2024 am IST			5-day change	1st Jan Change
1.545 ^USD	-0.96%		-3.32%	+56.06%

01/05	Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial	CI
01/04	Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

PROTAGENIC THERAPEUTICS, INC.NEW : Other Events (form 8-K)

September 03, 2022 at 02:04 am IST

Item 8.01 Other Events.

On Tuesday, August 30, 2022, the Company received CMC (Chemistry, Manufacturing and Controls) questions from a European regulatory authority requiring a response. Protagenic is addressing these questions and currently expects to commence clinical trials in the fourth quarter of 2022. In addition, the company is finalizing its US submission.

Latest news about Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial	01/05	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders	27/03	CI
Protagenic Therapeutics Achieves First Clinical Safety Milestone with Its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders	13/02	CI
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12/12	MT
Protagonist Therapeutics, Inc. Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals	12/12	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director	29/22/29	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	08/22/08	CI
Protagenic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	16/21/16	CI
Maxim Group Starts Protagenic Therapeutics at Buy with $4 Price Target	29/21/29	MT
Certain Warrant of Protagenic Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2021.	24/21/24	CI
Certain Common Stock of Protagenic Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2021.	24/21/24	CI
Certain Stock Options of Protagenic Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2021.	24/21/24	CI
Protagenic Therapeutics, Inc. Announces Audit Committee Changes	06/21/06	CI
Transcript : Protagenic Therapeutics, Inc. - Special Call	08/21/08
Protagenic Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	17/21/17	CI
Protagenic Therapeutics : Expects to Refile New Drug Application in Q4 After Implementing Change Requested by FDA	24/21/24	MT
Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial	24/21/24	CI

Chart Protagenic Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PROTAGENIC THERAPEUTICS, INC.	+56.06%	6.92M
MODERNA, INC.	+52.64%	63.85B
IQVIA HOLDINGS INC.	-2.50%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.41%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.46%	18.69B
BIO-TECHNE CORPORATION	+2.79%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.32%	12.11B
MEDPACE HOLDINGS, INC.	+27.78%	12.07B

Other Biotechnology & Medical Research